Genprex (NASDAQ:GNPX), Inc. is a clinical-stage gene therapy company focused on developing novel treatments for cancer and diabetes by leveraging its proprietary delivery platforms. Headquartered in Austin, Texas, the company is advancing multiple programs designed to address underlying causes of disease through targeted gene transfer. Genprex’s technology seeks to restore normal cellular function by introducing therapeutic genes directly to affected tissues, offering a differentiated approach compared to conventional small molecule and biologic therapies.
The company’s lead oncology program, Oncoprex immunogene therapy, delivers a tumor suppressor gene to cancer cells with the goal of enhancing the body’s immune response and sensitizing tumors to established treatments. In parallel, Genprex is advancing GemRIS, a depot-based hydrogel system engineered to provide sustained local delivery of therapeutic genes for diabetic peripheral neuropathy. Together, these platforms demonstrate the company’s commitment to platform diversification and address sizable unmet medical needs.
Since its founding, Genprex has established collaborations with leading academic and medical research institutions to support preclinical and clinical development efforts. The company’s programs have progressed through early clinical studies, and Genprex continues to engage with regulatory agencies and key opinion leaders to shape its development pathways. Manufacturing partnerships and in-house capabilities support scalable production of viral vectors and hydrogels under current good manufacturing practices.
Under the leadership of President and Chief Executive Officer James A. Christofferson and Executive Chairman Kenneth Mirkin, Genprex is focused on advancing its pipeline through clinical milestones and strategic partnerships. The management team combines industry veterans in gene therapy, clinical development, and commercial strategy, positioning the company to potentially bring its first therapies to patients in need. Genprex’s efforts reflect a vision of harnessing the power of gene-based medicine to transform treatment paradigms in oncology and metabolic diseases.
